STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

MAZE insider filing notes pro rata share distribution by TRV

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics (MAZE): Form 4 insider activity

Affiliates of Third Rock Ventures reported a pro rata, for-no-consideration distribution of 1,600,000 shares of Maze Therapeutics common stock on November 4, 2025, noted with transaction code J and described as exempt under Rules 16a-13 and 16a-9. Following the distribution, the filing shows 4,473,958 shares beneficially owned directly and 950,800 shares beneficially owned indirectly, with relationships indicated including director and 10% owner statuses and standard beneficial ownership disclaimers among the TRV entities.

Positive

  • None.

Negative

  • None.
Insider Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., TRV GP IV, LLC, Third Rock Ventures V, L.P., Third Rock Ventures GP V, LP, TRV GP V, LLC
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Type Security Shares Price Value
Other Common Stock 1,600,000 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 4,473,958 shares (Direct); Common Stock — 950,800 shares (Indirect, See Footnotes)
Footnotes (1)
  1. On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. The shares are held directly by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV LLC. Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Third Rock Ventures IV, L.P.
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
(Street)
BOSTON MA 02215
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/04/2025 J(1) 1,600,000 D (1) 4,473,958 D(2)(4)
Common Stock 950,800 I See Footnotes(3)(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Third Rock Ventures IV, L.P.
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
(Street)
BOSTON MA 02215
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Third Rock Ventures GP IV, L.P.
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
(Street)
BOSTON MA 02215
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
TRV GP IV, LLC
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
(Street)
BOSTON MA 02215
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Third Rock Ventures V, L.P.
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
(Street)
BOSTON MA 02215
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Third Rock Ventures GP V, LP
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
(Street)
BOSTON MA 02215
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
TRV GP V, LLC
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
(Street)
BOSTON MA 02215
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
2. The shares are held directly by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV LLC. Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
3. The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
4. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P. 11/05/2025
/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P. 11/05/2025
/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC 11/05/2025
/s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P., general partner of Third Rock Ventures V, L.P. 11/05/2025
/s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P. 11/05/2025
/s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC 11/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did MAZE insiders report in this Form 4?

A pro rata distribution of 1,600,000 Maze Therapeutics shares by Third Rock Ventures affiliates, for no consideration, on November 4, 2025.

What was the transaction code and treatment?

The filing lists code J and cites exemptions under Rules 16a-13 and 16a-9.

How many shares are shown as beneficially owned after the transaction?

The report shows 4,473,958 shares directly and 950,800 shares indirectly beneficially owned.

Was any cash consideration involved in the share movement?

No. The shares were distributed for no consideration.

Do the reporting persons claim full beneficial ownership?

Footnotes state beneficial ownership is disclaimed except to the extent of any pecuniary interest.

Is there a stated group under Section 13(d)?

The filing disclaims the existence of a Section 13(d) group between TRV IV and TRV V parties.